Potential Biomarkers in Heart Failure during training

Potential Biomarkers in Heart Failure during training - BERNHARDT

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00029306

Enrollment

Registered

2022-07-04

Start date

2023-01-03

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I50.9

Interventions

Group 1: Twenty patients with heart failure with preserved pump function (HFpEF) with exercise training experience will train either 12 weeks after WHO recommendation (T0-T1) or 12 weeks (T1-T2) of HI

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Full age - Heart failure with preserved pump function (HFpEF) - Cardio-pulmonary stable condition

Exclusion criteria

Exclusion criteria: - Additional training - Concomitant diseases that make training impossible (e.g. immobilization, myopathies) - Limited ability to cooperate - Pregnancy

Design outcomes

Primary

Measure	Time frame
- Improvement of cardiovascular performance of HFpEF patients by means of high-intensity interval endurance training (HIT) and strength training (HIRT) over 12 weeks (measured by spiroergometry, strength tests and echocardiography, among others). - Increase in the quality of life of the participating subjects (recorded via questionnaires PHQ9, WHO5, HADS) - Reduction of mitochondrial dysfunction and consequent optimization of mitochondrial performance of the study participants (recorded via blood analyses and evaluation of differential blood count, creatinine, urea, sodium, potassium, calcium, magnesium, phosphate, HbA1c, NT-pro BNP, lipids (total cholesterol, triglycerides, LDL- and HDL-cholesterol), CRP, ferritin, TSH, and the "mitochondrial panel": Galectin 3, Klotho, kynurenine, kynurenine and quinolinic acid, mtDNA/nDNA, musclin, NRF2, PGC1-alpha, rhodanase). => Primary endpoint assessment is performed immediately before training (T0), after 12 weeks (1st training phase T1) and after 24 weeks (completion of 2nd training phase T2)	—

Measure

Time frame

- Improvement of cardiovascular performance of HFpEF patients by means of high-intensity interval endurance training (HIT) and strength training (HIRT) over 12 weeks (measured by spiroergometry, strength tests and echocardiography, among others). - Increase in the quality of life of the participating subjects (recorded via questionnaires PHQ9, WHO5, HADS) - Reduction of mitochondrial dysfunction and consequent optimization of mitochondrial performance of the study participants (recorded via blood analyses and evaluation of differential blood count, creatinine, urea, sodium, potassium, calcium, magnesium, phosphate, HbA1c, NT-pro BNP, lipids (total cholesterol, triglycerides, LDL- and HDL-cholesterol), CRP, ferritin, TSH, and the "mitochondrial panel": Galectin 3, Klotho, kynurenine, kynurenine and quinolinic acid, mtDNA/nDNA, musclin, NRF2, PGC1-alpha, rhodanase). => Primary endpoint assessment is performed immediately before training (T0), after 12 weeks (1st training phase T1) and after 24 weeks (completion of 2nd training phase T2)

—

Secondary

Measure	Time frame
- Establishment and validation of a panel of mitochondrial biomarkers in HFpEF patients and healthy individuals. - Extension of the mitochondrial panel to other entities (e.g. obesity) - Establishment and expansion of long-term heart failure training groups according to the HIT/HIRT scheme in (supra-)regional networks.	—

Countries

Germany

Contacts

Public ContactAchim Jerg

Universitätsklinikum UlmZentrum für Innere MedizinSektion Sport- und Rehabilitationsmedizin

achim.jerg@uniklinik-ulm.de+49-731-500-45350

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026